Background The role of secondary cytomegalovirus (CMV) prophylaxis, defined as the
continuation of valganciclovir to prevent relapse after the successful treatment of CMV …

During a 38-month period, we studied 320 liver transplants in 283 recipients (202 adults, 81
children). CMV disease was documented in 85 patients (30.0%). The major risk factor for …

Despite increasing evidence in favor of prophylactic valganciclovir treatment in kidney
transplant recipients for the prevention of cytomegalovirus (CMV) infection, the impact of …

Background. Cytomegalovirus (CMV) prevention can be achieved by prophylaxis or
preemptive therapy. We performed a prospective randomized trial to determine whether …

Late‐onset cytomegalovirus (CMV) disease is a significant problem with a standard 3‐month
prophylaxis regimen. This multicentre, double‐blind, randomized controlled trial compared …

Background. We assessed the impact of a preemptive strategy after discontinuation of
antiviral prophylaxis in the prevention of late-onset cytomegalovirus (CMV) disease in a …

Aims: The aim of this study was to compare the efficacy and safety of two subsequent CMV
prophylaxis regimens for prevention of cytomegalovirus (CMV) infection and disease in our …

Prolonging cytomegalovirus (CMV) prophylaxis in CMV seronegative recipients of a kidney
from CMV seropositive donor (D+/R–) may reduce the incidence of late infections. We …

BACKGROUND: Late-onset CMV disease is being increasingly recognized as a significant
post-transplantation complication. OBJECTIVES: To discern the impact of antiviral …

We assessed the impact of antiviral prophylaxis and preemptive therapy on the incidence
and outcomes of cytomegalovirus (CMV) disease in a nationwide prospective cohort of solid …